Development

Michelle Hoffman, editorial director of Pharmaceutical Technology.

Articles

Individuals and companies at the top seem to have no problem short-circuiting their success.

Of Hubris and Happy Endings

Patricia Van Arnum was executive editor of Pharmaceutical Technology.

Leading contract manufacturing organizations share their views on the current and future market dynamics shaping pharmaceutical outsourcing.

Global Outsourcing: A Roundtable of Contract Manufacturers

Also, Isogen completes sterile facility; Dishman appoints head of generic API business; FDA releases final rule on authorized generic drugs and NDA submissions; more...

Company, People, and Regulatory Notes: Amgen and GSK Collaborate; WuXi Appoints VP of Pharmacology; More...

Also, Gilead and Tibotec form agreement; FDA approves 2009-2010 flu vaccine; Catalent appoints VP in packaging unit; more...

Company, People, and Regulatory Briefs: Teva and Ortho Extend Agreement; Biogen Idec Cofounder Retires; More...

Also, Lonza and Medarex sign agreement; Covance appoints VP and chief scientific officer of global analytical services; more...

Company and People Notes: Merck and Portola Sign Agreement; Eisai Appoints Senior Vice-Presidents; More ...

The Society of Chemical Manufacturers and Affiliates (SOCMA) this week stated its support to the US Senate for approving legislation that would extend existing chemical security standards for one more year.

SOCMA Supports Extension of CFATS

Also, Lundbeck acquired LifeHealth; FDA is seeking a director of its new tobacco regulation branch; Charles River Labs announces personnel changes; more...

Company and People Notes: Pfizer and Graceway Form Deal; GeoVax Labs Leader Resigns; More...

Johnson & Johnson has agreed to pay $1.0 billion to acquire the assets and rights of the Alzheimer's immunotherapy program of the biopharmaceutical company Elan, form a new company with Elan based on the AIP program, and gain an 18.4% stake in Elan.

J&J Invests $1.5 Billion in Deal with Elan

Advances in micellar catalysis, solid-state chemistry, catalytic asymmetric synthesis, and function-oriented synthesis for natural products represent noteworthy developments in green chemistry that can be applied to the synthesis of active pharmaceutical ingredients.

Deploying Green Chemistry in API Synthesis

Also, Wyeth and Catalyst sign agreement; FDA seeks public opinion about tobacco regulation; Catalent appoints VP of quality and regulatory affairs; more...

Ingredients